Your browser doesn't support javascript.
loading
Adherence to treatment in children with growth hormone deficiency, small for gestational age and Turner syndrome in Mexico: results of the Easypod™ connect observational study (ECOS).
Blanco-López, A; Antillón-Ferreira, C; Saavedra-Castillo, E; Barrientos-Pérez, M; Rivero-Escalante, H; Flores-Caloca, O; Calzada-León, R; Rosas-Guerra, C C; Koledova, E; Chiquete, E; Ayala-Estrada, A.
Afiliación
  • Blanco-López A; Hospital Ángeles Interlomas and Hospital Español, Mexico City, Mexico.
  • Antillón-Ferreira C; Hospital Español, Mexico City, Mexico.
  • Saavedra-Castillo E; Hospital de la Oca, Monterrey, Nuevo León, Mexico.
  • Barrientos-Pérez M; Hospital Ángeles, Puebla, Puebla, Mexico.
  • Rivero-Escalante H; Private Practice, Cancún, Quintana Roo, Mexico.
  • Flores-Caloca O; Hospital Zambrano Hellion, Monterrey, Nuevo León, Mexico.
  • Calzada-León R; Servicio de Endocrinología, Instituto Nacional de Pediatría, Mexico City, Mexico.
  • Rosas-Guerra CC; Merck Biopharma Distribution S.A. de C.V, Naucalpan de Juárez, Mexico.
  • Koledova E; Merck Healthcare KGaA, Darmstadt, Germany.
  • Chiquete E; Departamento de Neurología y Psiquiatría, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Delegacion Tlalpan, C.P. 14080, Ciudad de Mexico, México. erwinchiquete@hotmail.com.
  • Ayala-Estrada A; Servicio de Pediatría, Hospital ISSEMyM, Toluca, Estado de México, México. dr_arturo78@hotmail.com.
J Endocrinol Invest ; 43(10): 1447-1452, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32239476
ABSTRACT

BACKGROUND:

Assessing adherence to growth hormone (GH) is challenging. The Easypod™ connect device delivers pre-set doses of recombinant human GH (r-hGH) and stores a digital record of adherence that can be shared with healthcare provider. We assessed adherence to r-hGH delivered with Easypod™ according to the approved pediatric indications for r-hGH growth hormone deficiency (GHD), born small for gestational age (SGA) who failed to show catch-up growth and Turner syndrome (TS).

METHODS:

ECOS (NCT01555528) was a multicenter (24 countries), 5-year, longitudinal, observational study, which aimed to evaluate country-specific adherence to r-hGH therapy prescribed via the Easypod™ electronic injection device. The primary endpoint was yearly adherence. Secondary endpoints were height velocity, height velocity standard deviation scores (SDS), height, height SDS and IGF-1 concentrations. Clinical and auxological data were obtained from medical records and adherence from Easypod™ logs.

RESULTS:

This study included 147 Easypod™-naïve Mexican children assessed during 3 years (mean age 9.96 ± 3.41 years, 56.8% boys, mean height SDS at baseline - 2.17 ± 0.97) 118 with GHD, 24 SGA and 5 with TS. A total of 105 (71.4%) patients were GH naïve. Overall median adherence was > 90% over the first year of treatment and > 80% at 3 years. Adherence was not different by r-hGH indication or between GH-naïve or experienced patients. At 1-year follow-up, mean change in height SDS was 0.57 ± 0.34, whereas mean height velocity SDS was 2.85 ± 2.51. In all, 84.7% patients had normal IGF-1 concentrations at 1-year follow-up. Adherence was associated with change in height SDS (r = 0.239, p = 0.005) and height velocity SDS (r = 0.194, p = 0.027).

CONCLUSION:

Adherence rates with the Easypod™ device are high and maintained over time in GHD, SGA and TS Easypod™-naïve Mexican patients. High adherence is associated with better outcomes. Easypod™ assists physicians in monitoring adherence to r-hGH.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hormona de Crecimiento Humana / Cumplimiento de la Medicación / Trastornos del Crecimiento Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male / Newborn País/Región como asunto: Mexico Idioma: En Revista: J Endocrinol Invest Año: 2020 Tipo del documento: Article País de afiliación: México

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Hormona de Crecimiento Humana / Cumplimiento de la Medicación / Trastornos del Crecimiento Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Adolescent / Child / Female / Humans / Male / Newborn País/Región como asunto: Mexico Idioma: En Revista: J Endocrinol Invest Año: 2020 Tipo del documento: Article País de afiliación: México